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Abstract With finite resources, healthcare payers must
make difficult choices regarding spending and the ethical
distribution of funds. Here, we describe some of the ethical
issues surrounding inequity in healthcare in nine major
European countries, using cancer care as an example. To
identify relevant studies, we conducted a systematic liter-
ature search. The results of the literature review suggest
that although prevention, access to early diagnosis, and
radiotherapy are key factors associated with good out-
comes in oncology, public and political attention often
focusses on the availability of pharmacological treatments.
In some countries this focus may divert funding towards
cancer drugs, for example through specific cancer drugs
funds, leading to reduced expenditure on other areas of
cancer care, including prevention, and potentially on other
diseases. In addition, as highly effective, expensive agents
are developed, the use of value-based approaches may lead
to unacceptable impacts on health budgets, leading to a
potential need to re-evaluate current cost-effectiveness
thresholds. We anticipate that the question of how to fund
new therapies equitably will become even more challeng-
ing in the future, with the advent of expensive, innovative,
breakthrough treatments in other therapeutic areas.
Key Points for Decision Makers
Cancer survival varies among European countries
and is affected by socioeconomic status; prevention,
early diagnosis, and radiotherapy are key factors
associated with positive outcomes.
Fair reimbursement decisions regarding new
expensive drug therapies are a key part of the efforts
to improve equity in oncology care spending.
However, political attention can lead to prioritization
of funding for certain pharmacological treatments,
potentially reducing funding for cancer prevention
and the treatment of other diseases.
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1 Introduction
Most European healthcare systems fund medicines through
public reimbursement programmes, which aim to facilitate
equal access for citizens by eliminating or reducing direct
costs to patients. However, regulatory approval of a drug
does not guarantee patient access. Reimbursement author-
ities must assess the benefits of a therapy compared with
other available options and establish a fair price, which
may be lower than the manufacturer’s desired price. Con-
sequently, differences in the approaches, priorities and
budgets of different healthcare systems may lead to dif-
ferences in access to drugs between countries [1–3]. As
healthcare is ultimately funded by citizens and healthcare
resources are limited, payers must use their budgets sen-
sibly to improve health outcomes in the population for
which they are responsible. This can lead to difficult
choices regarding spending and the ethical distribution of
funds. Although the authors of this article are not ethicists,
in April 2015 we met to discuss some of the ethical issues
surrounding inequity in healthcare, as they affect payers in
the healthcare systems of the nine European countries in
which we work. We focussed our discussions on cancer
care, a major and increasing component of drug expendi-
ture. Starting from a definition of inequity proposed in
2011—‘‘Inequity is the presence of systematic and poten-
tially remediable differences among population groups
defined socially, economically, or geographically’’ [4]—
we agreed that therefore, ‘‘health equity is the fair allo-
cation of health determinants and resources in order to
maximise health outcomes in all segments of the popula-
tion, regardless of origin, social background and economic
differences.’’ This definition highlights resource allocation,
the aspect of health equity which payers can most readily
influence.
Global cancer expenditure has been estimated as
US$290 billion (£100 billion on cancer drugs alone in 2014
[5]), and spending is expected to reach US$458 billion by
2030 [6]. In 2009, cancer cost the European Union (EU)
€126 billion, with spending in France, Germany, Italy and
the UK accounting for two-thirds of the total [7]. With a
population increasing in size and age, cancer incidence and
the associated costs of treatment are expected to rise
worldwide in the coming decades [8–10]. Given the
exceptionally emotive nature of cancer, political focus
often centres on this therapy area above others, and in
particular on the availability of cancer drugs. Recently, the
rising cost of cancer treatments has forced many countries
to consider mechanisms to contain costs [11], with con-
cerns over potential bottlenecks in the funding of cancer
therapies [12]. However, any actions that may place
limitations on access to particular therapies are a potential
source of inequity.
In this article, we aim to use our real-life experience of
European healthcare systems to try to understand some of
the causes and consequences of inequity of access to cancer
care, with the hope that a common understanding of these
issues may aid the development of policies that can reduce
inequity. We conducted a literature review to identify rel-
evant publications, with a focus on cancer care as an
example (see supplementary material for literature review
methods). As well as identifying some of the variation
among European countries which may reflect differences in
healthcare system funding and organization, we discuss
healthcare funding priorities. In particular, we consider the
implications of the prioritization of certain interventions
through initiatives such as the 2011–2016 Cancer Drugs
Fund (CDF) in England.
2 Materials and Methods
To identify studies relevant to the review objectives, a
comprehensive, systematic literature search was conducted
in Embase, MEDLINE/MEDLINE In-Process, CINAHL,
PsycINFO, and the Cochrane Library on 24 December 2014.
The search strategy included controlled vocabulary and free
text terms, and the search results were filtered using the
countries of interest (Supplementary Table 1). The final
search results from each database were limited to studies in
humans published from 1 January 2009 in English. This time
frame was chosen to provide a comprehensive but recent
overview of the topic. To supplement the electronic database
search, the reference lists of studies identified in a prelimi-
nary, non-systematic search were manually screened.
All study types were included with the exception of
randomized controlled trials, clinical trials, case reports,
case series, case studies, and dissertations. Reviews were
included if the focus was on any or all of the countries of
interest or reported results for any of the countries of
interest. Articles evaluating any type of cancer were
included. Articles were included if they examined any type
of oncology care (prevention, screening, and treatment)
and addressed any of the following objectives: inequality
or inequity in access to oncology care in Europe; potential
consequences of inequity of access in Europe; ethical
issues regarding equity of access to oncology care in
Europe. The countries of interest were Belgium, England,
France, Germany, Italy, The Netherlands, Scotland, Spain
and Sweden. Articles on multiple countries were included
if they reported results from any or all of these countries
separately. In total, 15 relevant articles were identified
(Supplementary Fig. 1; Supplementary Table 2).
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3 Results
3.1 Differences in Healthcare and Outcomes Among
Countries
Inequity in access to cancer treatment is known to have a
measurable impact on patient outcomes [13, 14]. In Eur-
ope, the recent EUROCARE studies have investigated
differences in cancer treatment and 5-year survival rates
across European countries [13, 14]. All-cancer 5-year
survival ranged from 37 % in Slovakia to 61 % in Sweden,
and correlated linearly with spending (R = 0.8; spending
was adjusted to take account of the varying purchasing
power of national currencies). In general, countries with
high spending had high numbers of diagnostic and radio-
therapy units, and the number of magnetic resonance
imaging (MRI) units per capita directly correlated with
survival (R = 0.7), reflecting the importance of early
diagnosis. Surprisingly, given the political focus on cancer
drugs, 5-year survival was more closely linked to the
availability of radiotherapy units than to overall healthcare
spending, highlighting the importance of efficient resource
allocation [13]. A similar analysis used data from the
EUROCARE-5 study of 107 cancer registries in Europe to
investigate 5-year survival rates for ten common cancers
[14]. Countries with high national expenditure on cancer
care generally had higher survival rates than those with low
expenditure. However, differences among countries with
high levels of healthcare spending demonstrated that other
factors influence survival rates. Some of these differences
may reflect an uneven distribution of different cancer
types; for example, the incidence of melanoma in Sweden
is approximately three times that in Spain [15]. For patients
with similar cancers, comparisons between countries are
complicated by a number of factors influencing survival.
Explanations for differences in survival between countries
may include differences in rates of early diagnosis [16–18],
accessibility of medical care other than cancer drugs, dif-
ferent diagnostic intensity and screening approaches, and
differences in cancer biology [14]. However, variation in
survival may also be a result of differences in socioeco-
nomic status, general health and lifestyle factors (for
example, prevalence of smoking) [19].
In addition to the absolute level of expenditure, the
organization of care within a healthcare system can
improve both efficiency and outcomes. For example, the
German certification process for cancer centres is intended
to promote collaboration of the various disciplines
involved in cancer care, including diagnosis, therapy and
aftercare. Such an integrated approach can improve the
quality of healthcare processes, as well as treatment satis-
faction and outcomes for patients [20]. In addition, there
are differences among countries in the availability and
funding of cancer screening programmes (for example,
Germany is the only country in which skin cancer
screening is a standard benefit of public health insurance).
3.2 Differences in Healthcare and Outcomes Within
Countries
As well as access at an international level, local socioe-
conomic and personal factors also influence access to
cancer care, and this potential source of inequity is a sig-
nificant concern for payers within healthcare systems.
Across Europe, socioeconomic status, primarily education
level and employment status, has been found to have a
significant effect on the uptake of cancer screening, even
among individuals otherwise using the healthcare system
[21–27].
Where screening programmes are available, there is
significant variation in the uptake of screening for prostate
cancer, breast cancer and cervical cancer [21, 25]. In each
case, education levels and/or employment type appear to be
significant determinants of screening rates when individu-
als were required to initiate screening. At a local level,
several studies have identified differences in cancer
screening rates according to socioeconomic factors, par-
ticularly education [22–24, 26, 27]. We note that in addi-
tion to taking steps to improve access to screening, it is
important for payers to consider which types of cancer
screening are beneficial. For example, population-wide
prostate cancer screening is associated with only small
reductions in mortality, but over-diagnosis and over-treat-
ment are common, and are associated with treatment-re-
lated harms [28].
Socioeconomic factors also affect the incidence of par-
ticular cancer types and the likely stage at diagnosis
[29–32]. In addition, both the speed of treatment initiation
and the type of treatment received by patients appear to be
negatively influenced by low education and deprivation
[33, 34]. For example, a retrospective study in the UK
found that patients in affluent areas are more likely to
receive treatment for colorectal cancer within 6 months of
their first contact with the National Health Service (NHS)
than those in deprived areas [34]. Among those receiving
treatment, the most deprived patients were less likely to
receive treatment within 1 month than the most affluent
group, and more likely to receive treatment only after 4–6
months. The most deprived patients were also less likely to
survive for 3 years after diagnosis; this difference appears
to reflect the delay in treatment initiation [34]. It is possible
that patients in the most affluent groups are also likely to be
better educated than other groups, and may be more able to
seek appropriate and high-quality treatment [34]. The
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impact of education level on treatment outcomes has been
seen in many studies, including a Swedish analysis that
identified significantly higher rates of 5-year colorectal
cancer survival for highly educated patients than for those
with low education [33]. Similarly, in France a mortality
gradient has been described from north to south along the
RER B train line which links wealthy central Paris with
less affluent suburbs [35].
3.3 Differences in Reimbursement Decision-Making
for Medicines in Europe
Health outcomes are also affected by the availability of
therapies for patients’ specific diseases. Following
approval by the European Medicines Agency (EMA),
medications that have demonstrated a favourable safety
and efficacy profile in evidence-based clinical trials may or
may not be granted market access by national health
technology assessment (HTA) agencies [1–3]. A recent
study evaluated inter-country variability in access by
reviewing the number of indications reimbursed by public
drug programmes for 10 cancer drugs [3]. Reimbursement
varied significantly across Europe, with HTA bodies in
England and Scotland recommending for reimbursement
fewer than half of 44 indications approved by EMA, mostly
owing to a lack of cost effectiveness. However, in several
cases in England and Scotland indications that were not
initially recommended for reimbursement were subse-
quently approved with risk-sharing agreements or patient
access schemes, or were funded through the CDF
[3, 36, 37]. Payers have responsibility for healthcare sys-
tems as a whole rather than just oncology, and may
sometimes make difficult decisions to limit access to some
agents in order to ensure the sustainability of the entire
healthcare system. However, in the experience of the
authors, payers often take steps to optimize access to
effective treatments, even to the extent of overcoming
initial negative decisions.
3.4 Healthcare Funding Priorities in Europe
Finite resources mean that governments and payers have to
decide on the priorities for their individual healthcare
systems. Although access to early diagnosis and radio-
therapy are the key factors associated with good outcomes
in oncology [13, 16–18], public and political attention
often focusses on the availability of cancer drugs [8]. In the
EU, cancer drug costs represented 27 % of direct health-
care costs due to cancer in 2009, with considerable varia-
tion among countries—in France drug costs were 43 % of
the total, compared with 17 % in the Netherlands. This
variation may reflect differences in the focus of cancer care
spending, although caution is needed when comparing non-
drug expenditure due to differences in funding systems and
healthcare labour costs [7]. In 2009, Germany spent
slightly less than France on cancer drugs, but had double
the cancer care budget overall [7], suggesting greater
expenditure on other aspects of care, such as access to
diagnostic and radiotherapy facilities, which have a sig-
nificant impact on cancer outcomes [14]. The use of cancer
drugs can also vary within a single healthcare system, as
shown in a recent analysis in the Netherlands, which found
a large variation in the use of particular (expensive)
oncology drugs between hospitals [38].
Reimbursement decisions reached through HTA pro-
cesses [e.g. cost-effectiveness analysis (CEA)] can
sometimes be bypassed by alternative mechanisms. For
example, from 2011 to 2016 cancer drugs not available
through the NHS in England owing to their high cost
could be funded by the CDF. However, while the CDF
has benefited some patients with cancer, there was a
significant level of criticism of this approach, from the
National Institute for Health and Care Excellence (NICE)
among others [39]. In 2015, an analysis of the costs of a
quality-adjusted life-year (QALY) in the healthcare sys-
tem as a whole suggested that the policy decision to fund
expensive therapies through the CDF may have had a
detrimental effect on care for patients with non-cancer
diseases, and that making the CDF’s budget available to
the wider NHS would result in much greater improve-
ments in survival and quality of life overall [40]. In
response to the financial pressure on the CDF, a new
framework was adopted in July 2016 [41]. In this
framework, new therapies considered by NICE to be
potentially cost effective, but around which there is con-
siderable clinical uncertainly, can be recommended for
interim funding through the CDF. The CDF will then
operate as a managed access fund, with the level of
reimbursement for each therapy agreed between NHS
England and the manufacturer, and monitoring of patient
and population outcomes. After a data collection period of
up to 2 years, each therapy will be reappraised by
NICE—it is intended that the reappraisal outcome will be
a final positive or negative recommendation.
In addition to the criticism of the 2011–2016 CDF
described above, it has been suggested that even when new
drugs are deemed cost effective by NICE, the threshold
used may be too high [40]. New therapies are typically
considered to be cost effective if their incremental cost-
effectiveness ratio (ICER), the cost of gaining a fixed
improvement in health outcomes compared with existing
therapies, is below £30,000 per QALY, with this threshold
extended to approximately £50,000 for therapies that can
extend life by at least 3 months (typically cancer therapies)
[42]. However, NHS expenditure overall was estimated to
generate 1 QALY for every £13,000 spent, suggesting that
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displacement of existing treatments to fund new, expensive
therapies might lead to a net loss of QALYs [40].
These studies raise important issues, and highlight the
need for payers to consider the impact of reimbursement
for new therapies beyond the patient population in ques-
tion. The approach taken by NICE in the UK, and by
payers across Europe, is more complex than an attempt to
maximise QALYs across the healthcare system, and in
many cases includes a willingness to encourage the
development of innovative new medicines and devices
[43]. However, while all payers aim to provide patients
with access to the most effective treatments, ultimately
with curative intent, it is also important that funding can be
provided for other aspects of cancer care, including
screening, early diagnosis, radiotherapy and palliative care.
At a national level, individual countries’ cancer plans take
into account all aspects of care. However, it is possible that
initiatives such as the 2011–2016 CDF may divert funding
towards cancer drugs, leading to reduced expenditure on
early diagnosis and radiotherapy, and thereby potentially
doing harm to care outcomes overall. As well as allocating
resources appropriately within cancer care, payers must
also ensure that other disease areas are treated fairly, both
in terms of managing major costs to the healthcare system
in other areas and of avoiding cuts to budgets in areas that
may be less costly and less high profile than oncology, but
represent good value for money [40].
In some countries, for example Germany, the healthcare
system does not give priority to particular disease areas.
However, funding arrangements such as the CDF exist in a
number of other countries, demonstrating a political will-
ingness to overturn technical decisions on reimbursement.
For example, the Italian government has established a fund
to reimburse the costs of new innovative medicines, as well
as a separate fund for new hepatitis C drugs, although with
restrictions on the number of patients to be treated. A fund
for new hepatitis C treatments has also been set up in the
UK. A number of therapies for orphan diseases have also
been made available through special earmarked funds. In
each case, funding of one disease area over another is
potentially problematic—in the UK at least this may
undermine the fundamental NHS principle that all patients
should be treated equitably. If funding is to be allocated
according to the priority assigned to different disease areas,
this raises a fundamental problem: how does one decide
whether it is worse to have cancer than another disease
such as heart failure? In systems that make use of the
QALY in order to compare health outcomes across dif-
ferent disease areas (‘‘a QALY is a QALY is a QALY’’)
[44] it is not obvious that there should be a willingness to
pay more for a QALY in one disease area than in another.
It is theoretically possible that in a particular country,
society as a whole may decide that increased funding
should be given to cancer therapies, even at the expense of
other disease areas. If this is the case, rather than overriding
the decision-making processes of HTA bodies, it may be
more effective to capture such societal preferences through
evaluation approaches such as value-based assessment. In
principle, such processes could allow prioritization of the
use of healthcare budgets without leading to inequity of
access from the perspective of society. More general
attempts have also been made to take the views of patients
and of society as a whole into account in reimbursement
decision making. In the Netherlands, the National Health-
care Institute has recently announced that willingness-to-
pay levels for new therapies will be weighted according to
disease burden [45]. In Belgium, a recent ‘‘citizens’ lab’’
initiative has revealed that society seems to favour quality
of life and longer-term benefits as major criteria for reim-
bursement of novel therapeutics [46]. In addition, the
Scottish Medicines Consortium, will accept more uncer-
tainty in the economic case for medicines licensed for the
treatment of orphan diseases, and will accept a higher
ICER for treatments providing a substantial improvement
in life expectancy [47]. NICE also consider life extension
at the end of life, as well as innovation and the non-health
objectives of the NHS [48]. Recently, further proposed
‘modifiers’—including burden of illness and wider societal
impact have been investigated in public preference surveys
[49–51]. Although proposals to prioritize innovative
treatments and those for severe diseases were broadly
supported [49, 51], results were inconsistent with regard to
an end-of-life premium [49–51]. Participants in one study
reported a substantial preference for health-related quality
of life improvement over life extension [50]—in oncology,
this may suggest that greater attention should be paid to the
side-effect profiles of therapies, and to the role of palliative
care.
3.5 Legal Implications of Healthcare Decision-
Making
Ultimately, the consequence of any system of decision
making in healthcare is that some therapies may not be
made available to patients. In addition to the need to avoid
possible inequity, the legal system in each country must be
considered. In the UK, access to a drug cannot be rejected
absolutely for any reason other than safety. Although it
would in most cases be politically and ethically difficult to
justify, rationing based on evidence and within equality
legislation is not illegal [52]. In Sweden, rationing is
allowed in the context of prioritization, provided allocation
of treatment is done in a transparent manner [53]. In Bel-
gium the legal system does not cover rationing. The
Spanish Constitution is ambiguous: rationing beyond
national processes is possible through regional
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reimbursement decisions, but is unlikely to be supported by
the courts, which cannot back restrictions on a publicly
available drug. In France, reducing social inequalities for
those affected by cancer is the main goal of the 2014–2019
national cancer plan [54]. The influence of these differ-
ences is not straightforward, and in some cases there may
be potential for legal challenges to decisions made in the
interests of equitable distribution of healthcare resources.
3.6 Sustainability of Healthcare Funding
Much debate focusses on the possibility of funding
expensive treatments. However, from a payer perspective it
is at least as important to consider whether the price levels
that force payers and politicians into the current discus-
sions and conflicts are sustainable. Overall, drug expendi-
ture has risen significantly in recent years, and in countries
such as Germany has almost doubled since the beginning
of the century. Particularly in oncology, with new treat-
ment options and combination therapies available in the
near future, it is likely that the response from healthcare
systems will not be limited to attempts to prioritize or to
increase budgets. In addition, we may expect in the future
to see an introduction of some pricing elements based on
development and manufacturing costs. Pricing using a
purely value-based approach may lead to therapies being
deemed cost effective under current thresholds, but having
an ultimately unaffordable impact on healthcare budgets.
CEA (which is less central to decision making in European
countries such as France and Germany than in the UK and
Sweden) is therefore only part of the solution to funding
costly medicines. Where CEA is a major factor in decision
making, it has been suggested that lower cost-effectiveness
thresholds may be needed for therapies with a very large
budget impact [40].
4 Discussion
Cancer is a leading cause of death and morbidity
throughout the world, and an increasing component of total
healthcare spending. Consideration of the cost of cancer
care raises questions regarding how healthcare payers
balance access, quality, equity and cost. Essentially, all
countries must ration healthcare to some extent, but ques-
tions exist around how this should be accomplished, and
whether there is political and public agreement with the
chosen approach. As a result, there are substantial differ-
ences in healthcare and outcomes between European
countries. Many of these differences represent substantial
equity issues that cannot readily be addressed by healthcare
payers and decision makers within a specific country.
However, differences between countries can provide
insights that can be used to improve healthcare within an
individual system. Indeed, inequity within countries—dif-
ferences in treatment and outcomes that are related to
socioeconomic or geographical factors—remains a serious
concern in Europe. It is possible to address some of the
sources of inequity through organizational approaches,
such as a national cancer plan, designated cancer centres,
routine provision of second opinions and the integration of
care to provide patients with a single point of contact.
Educational measures aimed at improving health literacy
are also likely to be beneficial, particularly in improving
early diagnosis and treatment. Fair reimbursement deci-
sions regarding new expensive drug therapies are also a
key part of the efforts to reach better equity in oncology
care spending.
Reimbursement decisions should be taken with the aim
of making effective therapies available to patients while
avoiding an inequitable distribution of resources. In a
healthcare system with a finite budget, this may mean that
in some cases negative decisions are appropriate. By
contrast, prioritization of certain disease areas, particu-
larly cancer, through political initiatives may have unin-
tended consequences for the healthcare system as a
whole. By ring-fencing funds for one aspect of healthcare,
other, potentially more cost-effective areas may have their
budgets reduced. More widely, funding drug therapies in
a fair way is challenging, with effective, innovative
agents often associated with high costs. There is some
evidence that society as a whole may support prioritiza-
tion of therapies in certain areas, particularly cancer. As
members of society are ultimately the funders of our
healthcare systems, it may be that a higher willingness to
pay is appropriate in some disease areas—this is the
subject of ongoing research in a number of countries. It is
therefore likely that price structures and valuation models
may change in the future. For example, payers have
suggested innovative pricing strategies for gene therapies
which may lead to price levels that are more sustainable
in the long term [55]. The question of how to fund new
therapies equitably is a major issue at present, and is
likely to become even more challenging in the future,
with the advent of expensive, innovative, breakthrough
treatments.
This review has some limitations. In particular, equity in
oncology care is affected by a number of factors, and the
rapidly evolving systems and processes across Europe
makes the identification of the causes of inequity chal-
lenging. However, the authors as a group have noted dif-
ferences in equity among the countries in which we work,
and believe that our real-life experience has allowed us to
identify some of the key issues in oncology funding, with
the goal of furthering a common understanding of equity in
healthcare.
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In conclusion, the findings of this review suggest that
there is a high degree of awareness of inequity in cancer
care in Europe. Payers attempt to allocate budgets fairly,
while following the preferences of patients and society
where possible. Given budget constraints, however, deci-
sions on spending and drug reimbursement inevitably
affect equity, either directly by limiting access to a par-
ticular treatment, or indirectly by reducing the funding
available in other areas. Several different methods are used
in European countries to justify funding decisions, based
on a number of criteria. Future research is needed to
advance our understanding of the complexity of the causes
of differences in outcomes, and to help develop new
policies aimed at reducing inequity.
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